Advanced Solid Tumor Clinical Trials in Nashville, Tennessee

31 studies are recruiting for advanced solid tumor in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Study of YL242 in Subjects With Advanced Solid Tumors

   This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   US-205, Nashville, Tennessee

   Locations

   15 in total

   Run by

   MediLink Therapeutics (Suzhou) Co., Ltd.

   See if you can join NCT07197827 on ClinicalTrials.gov

2. JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

   This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   10 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT06108050 on ClinicalTrials.gov

3. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

   This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville, Tennessee

   Locations

   14 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06241456 on ClinicalTrials.gov

4. A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #6, Nashville, Tennessee

   Locations

   16 in total

   Run by

   Exelixis

   See if you can join NCT05932862 on ClinicalTrials.gov

5. Study of SGR-3515 In Participants With Advanced Solid Tumors.

   The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   14 in total

   Run by

   Schrödinger, Inc.

   See if you can join NCT06463340 on ClinicalTrials.gov

6. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

   This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study wil…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   6 in total

   Run by

   Edgewood Oncology Inc.

   See if you can join NCT04872166 on ClinicalTrials.gov